You just read:

Soligenix Announces $1.5 Million NIDCR SBIR Grant Award Supporting the Pivotal Phase 3 Clinical Trial of SGX942 for the Treatment of Oral Mucositis in Head and Neck Cancer

News provided by

Soligenix, Inc.

Sep 20, 2017, 06:00 ET